Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Kisunla, a newly approved Alzheimer's drug in Taiwan, would not be covered by the National Health Insurance (NHI) system, ...

Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.